Natera Inc

12 okt 2026, 20:06 UTC

Natera Inc shares are declining, pulling back from an earlier high, despite being nominated for the 2026 Future Investors Awards as a top healthcare company.

9 okt 2026, 20:07 UTC

Natera Inc.'s multi-cancer early detection assay received Breakthrough Device designation from the FDA, aimed at improving early cancer diagnosis and treatment options.

8 okt 2026, 20:07 UTC

Baird analyst Catherine Ramsey Schulte raised Natera Inc's price target to $458.00 from $376.00 while maintaining an Outperform rating.

7 okt 2026, 20:00 UTC

Natera Inc. shares fell despite the enrollment of patients in a study for advanced melanoma and Barclays raising its price target to $475 from $340.

6 okt 2026, 20:00 UTC

Natera Inc shares fell amid broader biotechnology sector weakness, despite positive data on its Signatera product and Citigroup raising its price target to $480.

5 okt 2026, 23:05 UTC

Citi raised its price target on Natera Inc to $480 from $365, maintaining a Buy rating amid growth in its Signatera product and health segments.

2 okt 2026, 20:07 UTC

Natera Inc shares are higher amid a broadly advancing market, reflecting positive momentum as labor statistics influence expectations for future interest rates.

1 okt 2026, 20:07 UTC

Natera Inc shares are declining, reversing earlier gains despite remaining above the 20-day moving average and near the upper end of the one-month range.

30 sep 2026, 23:00 UTC

Natera Inc declined in after-market trading, settling below Wednesday's close after retreating from an early high, despite remaining higher over the past month.

29 sep 2026, 19:15 UTC

Natera Inc shares are modestly higher as social media buzz highlights positive cash flows and a potential cancer screening test amid market volatility.

28 sep 2026, 20:07 UTC

Natera's shares fell amid a broader market decline, despite RBC Capital raising its price target to $460 and maintaining an Outperform rating.

25 sep 2026, 19:46 UTC

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.

24 sep 2026, 23:01 UTC

Natera Inc is trading modestly lower in after-market hours, having retraced from an early gain and reflecting a cumulative decline since Thursday's close.

22 sep 2026, 20:02 UTC

Natera Inc's Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, driving the stock sharply higher.

21 sep 2026, 22:11 UTC

Natera Inc is trading modestly higher in after-market hours, remaining well above its 20-day moving average following a peak earlier in the session.

18 sep 2026, 22:31 UTC

Natera Inc declined in after-market trading, moving lower since Friday's close, despite previously trading above its 20-day moving average.

17 sep 2026, 23:06 UTC

Natera Inc's shares traded flat in after-market hours, remaining 10.18% above the 20-day moving average amid positive economic indicators.

16 sep 2026, 19:07 UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

15 sep 2026, 23:01 UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

14 sep 2026, 19:26 UTC

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.

11 sep 2026, 22:51 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing trading.

9 sep 2026, 20:07 UTC

UBS has raised its price target on Natera Inc. to $435, maintaining a Buy rating and contributing to a rise in shares during Wednesday's session.

8 sep 2026, 23:06 UTC

Natera Inc. shares are higher in after-market trading, maintaining upward momentum since Tuesday's close despite an earlier pullback. The stock is above its 20-day moving average.

3 sep 2026, 19:36 UTC

Baird raised Natera's price target to $376 from $348, maintaining an Outperform rating. Shares are higher since Wednesday's close amid easing interest rate concerns.

2 sep 2026, 23:26 UTC

Natera Inc. shares are higher in after-market trading, continuing a strong performance over the past month, well above the 20-day moving average.

1 sep 2026, 19:36 UTC

Natera's Signatera test shows 100% predictive value for lymphoma treatment responses, boosting shares higher during Tuesday's session.

31 aug 2026, 23:01 UTC

Natera Inc shares are higher in after-market trading, stabilizing near earlier highs amid broader economic concerns over potential interest rate hikes.

28 aug 2026, 20:02 UTC

Natera Inc partners with Susan G. Komen to enhance breast cancer education. Shares are lower amid high trading volume and broader market pressures.

27 aug 2026, 20:07 UTC

Natera partners with Angiex to use Signatera in a Phase I trial for AGX101, aimed at enhancing cancer treatment response evaluation. Shares are roughly flat.

26 aug 2026, 19:26 UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.